In a Skyla vs Kyleena comparison, the two real differences are hormone content and labeled duration, not device size. Skyla contains 13.5 mg of levonorgestrel and is approved for up to 3 years; Kyleena contains 19.5 mg and is approved for up to 5 years. Both are estrogen-free levonorgestrel intrauterine systems from the same manufacturer, and both use an identical 28 mm by 30 mm T-frame with a 3.8 mm inserter tube. For clinic teams, that means selection turns on replacement horizon, bleeding expectations, contraindication screening, and consistent counseling language, rather than on inserter fit.
The distinction matters because shorthand like “the smaller one” or “the low hormone one” sends counseling off in the wrong direction. Label-based wording keeps consent accurate, reduces avoidable follow-up calls, and makes charting easier to audit across providers.
The Short Version
- Same frame, same inserter diameter: neither device is physically smaller than the other.
- Hormone load differs: 13.5 mg versus 19.5 mg of levonorgestrel per device.
- Duration differs: up to 3 years versus up to 5 years on the US label.
- Neither is estrogen-containing, and neither is a nonhormonal method.
- Spotting, irregular bleeding and cramping are expected early with both.
- Neither is FDA-approved for heavy menstrual bleeding; that use would be off-label.
Skyla vs Kyleena at a Glance
Both products sit in the same drug and device class, so the shared features outnumber the differences. Each releases levonorgestrel locally into the uterine cavity, each carries a silver ring on the vertical stem to aid identification on ultrasound, and each is indicated in the United States for prevention of pregnancy for its labeled duration. The table below summarizes what the prescribing information actually separates.
| Factor | Skyla | Kyleena | Why it matters in clinic |
|---|---|---|---|
| Levonorgestrel content | 13.5 mg | 19.5 mg | Total drug load differs; it does not predict individual tolerability |
| Approximate release | About 14 mcg/day after 24 days, falling over time | About 17.5 mcg/day after 24 days, falling over time | Both decline across the use period per label |
| Labeled duration | Up to 3 years | Up to 5 years | Drives replacement scheduling and consent language |
| Frame and inserter | 28 mm x 30 mm T-frame, 3.8 mm inserter | 28 mm x 30 mm T-frame, 3.8 mm inserter | Size is not a tie-breaker between these two |
| Estrogen | None | None | Relevant when estrogen is being avoided, not when hormones are |
| Typical early course | Spotting, irregular bleeding, cramping | Spotting, irregular bleeding, cramping | Expectations should be set before placement |
The size point deserves repeating because it is the most common error in staff scripting. Within this pair, the inserter diameter is the same, so a difficult insertion is not solved by switching brands. Uterine position, cervical stenosis, prior procedures, technique and operator experience carry far more weight. Both inserters are narrower than the 4.4 mm tube used for the 52 mg device, which is where the “smaller IUD” shorthand probably originated.
Why it matters: Two devices with identical dimensions can still produce very different replacement timelines.
Hormone Content Without Marketing Shorthand
Both devices are hormonal, so the question is never whether one is hormone-free. Levonorgestrel is a progestin, and the main contraceptive effects are local: thickened cervical mucus, suppressed endometrium and inhibited sperm function, with ovulation often preserved. Skyla releases roughly 14 mcg per day after the first 24 days, declining to about 5 mcg per day at 3 years, according to the current Skyla prescribing information. Kyleena starts near 17.5 mcg per day and declines across its 5-year window.
If a patient asks whether Skyla lowers estrogen, the answer is no. It is an estrogen-free contraceptive, not an estrogen-suppressing therapy. Estrogen-free and nonhormonal are also not interchangeable, and teams sometimes use them as if they were. The copper IUD is the nonhormonal option; these two are not.
“Lowest hormone IUD” is not a regulated or standardized category. Skyla does hold less levonorgestrel than Kyleena, but lower total content is not a promise of fewer systemic symptoms, lighter bleeding or better tolerance. Systemic levonorgestrel exposure from both devices is low compared with oral progestin regimens, and individual response still varies. Documenting prior contraceptive experience, and the reason any earlier method was stopped, tells you more than a hormone ranking phrase.
Bleeding Patterns, Side Effects and Weight Questions
Expect bleeding changes with both devices, particularly in the first three to six months. Irregular spotting and unpredictable bleeding are the most frequent early complaints, and patients often read them as device failure or malposition when they were not warned in advance. Over time, bleeding usually becomes lighter and less frequent. Amenorrhea occurs in a minority of users and becomes more common the longer the device is in place; it is reported less often with these lower-dose systems than with 52 mg levonorgestrel devices.
Weight change comes up constantly in this comparison, and the honest answer is that neither label establishes clinically meaningful weight gain as a drug effect. Weight increase appears among reported adverse reactions for progestin methods, but the available evidence does not show that levonorgestrel intrauterine systems cause substantial weight gain, and no reliable data separate the two devices on this point. Acne, breast tenderness, headache, ovarian cysts and mood changes can also be reported with either. None of them is a dependable tie-breaker.
A more useful counseling frame is time-bound: describe the expected early pattern, state when you want to hear from the patient, and set a follow-up point rather than promising a particular bleeding outcome. That approach keeps documentation consistent and avoids overpromising based on hormone content.
Shared Class Warnings and Escalation Points
The safety profile is broadly similar because the class is the same. Counseling should cover expulsion, uterine perforation, pelvic infection around the time of insertion, ovarian cysts, and ectopic pregnancy if conception occurs with a device in place. Screening for sexually transmitted infection, current pelvic infection, unexplained uterine bleeding, uterine anomaly distorting the cavity, known or suspected pregnancy, and known or suspected breast cancer follows standard practice; the CDC guidance on intrauterine contraception for clinicians remains the practical reference for timing, screening and problem management.
Give patients a plain escalation list and chart that you gave it:
- Severe or escalating pelvic pain: evaluate promptly.
- Fever or chills after placement: consider infection workup per protocol.
- Heavy or prolonged bleeding: assess against the expected post-placement course.
- Missing or lengthened strings: image to exclude expulsion or malposition.
- Positive pregnancy test with device in situ: exclude ectopic pregnancy urgently.
None of these warnings separates the two products, which is exactly why a safety-first comparison rarely settles the choice on its own.
Where Each Device May Fit in Selection
Duration is the practical divider. The Kyleena prescribing information supports up to 5 years of use, which can reduce exchange procedures across a defined care window and simplify recall scheduling. A 3-year label may suit a patient planning pregnancy within a shorter horizon, or one who wants a shorter initial commitment to a hormonal intrauterine method and is comfortable with an earlier review point.
When this pair is the right comparison
Choose inside this pair when the patient wants an estrogen-free intrauterine method, is comfortable with a progestin, and the open questions are replacement timing and expected bleeding pattern. In that scenario, the Skyla vs Kyleena decision is largely a scheduling and counseling decision, documented against the label.
When the comparison should widen
Move outside the pair when the goal is nonhormonal contraception, in which case copper intrauterine contraception is the relevant pathway. Widen it again when the patient wants the longest available labeled duration or treatment for heavy menstrual bleeding, since neither of these two devices carries that indication in the United States and the 52 mg systems do. Framing the choice too narrowly is the most common counseling failure here, more common than any mix-up about hormone content.
Handling, Documentation and Procurement Notes
Operational detail is where a clean comparison earns its keep. Verify storage and handling against the current manufacturer instructions for the specific product rather than assuming parity with another intrauterine system on your shelf; sterile packaging integrity, expiry and single-use handling are checked at receipt and again before placement. Procurement should follow the same discipline: Med Wholesale Supplies is a wholesale supplier of aesthetic, orthopedic and medical products to clinics, hospitals and medical professionals, operating since 2013, and any supplier a practice uses should provide product supplied for licensed professional use with traceable lot documentation.
- Confirm current labeling, indication and duration before counseling.
- Screen contraindications, pregnancy status and infection risk per protocol.
- Record bleeding goals, prior contraceptive history and intended duration of use.
- Document lot number, expiry, insertion details and consent elements.
- Check storage, packaging integrity and handling against manufacturer instructions.
- Standardize red-flag instructions and the follow-up pathway across all staff.
- Enter the replacement date at the time of insertion, not at the first follow-up.
Quick tip: Keep one scripted answer for size, hormone content and estrogen status so every provider says the same thing.
Scripting consistency prevents the three errors that show up most in audits: calling one device smaller when the frames match, summarizing the choice as “low hormone” without explaining duration or class warnings, and leaving the replacement horizon off the initial note. Each one is small. Together they distort consent and make handoffs between providers less reliable.
What This Comparison Cannot Settle
There is no healthiest intrauterine device in general, and this comparison does not produce one. What a label-based Skyla vs Kyleena review can settle is narrow and useful: hormone content, release profile, labeled duration, dimensions and estrogen status. What remains clinical work is everything else, including history, exam findings, contraindication screening, bleeding priorities and the patient’s own planning horizon.
For procurement and formulary conversations, the same limit applies. Stocking decisions should follow the population served, the training of the inserters and the documentation standards the practice must maintain, not consumer shorthand about which device feels gentler. When the underlying question points beyond this pair, widen the discussion rather than forcing an answer inside it. Current prescribing information from the manufacturer and CDC contraception guidance remain the controlling references for every point above.
This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified clinician or pharmacist about your situation, and seek urgent care or call your local emergency number for severe or worsening symptoms.







